BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB
Dubinsky M, Schreiber S, Matsuoka K, Jairath V, Al-Bawardy B, Pellanda P, Zhu B, Bleakman A, Redondo I, Owen C, Limdi J. BASELINE PROGNOSTIC FACTORS OF BOWEL URGENCY IMPROVEMENT IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB. Inflammatory Bowel Diseases 2025, 31: s62-s63. DOI: 10.1093/ibd/izae282.147.Peer-Reviewed Original ResearchNumerical rating scalePain numerical rating scaleModified Mayo scoreMultivariate linear regression analysisInflammatory Bowel Disease QuestionnaireUnivariate analysisUlcerative colitisMayo scorePrognostic variablesAnti-IL-23p19 antibodyBaseline characteristics of patientsAnti-IL-23p19Linear regression analysisPhase 3 trialRegression analysisCharacteristics of patientsUrgency Numeric Rating ScaleBristol Stool ScaleMultivariate regression analysisPost hoc analysisUnivariate analysis of associationPrognostic factorsDisease extentBaseline characteristicsMirikizumabColorectal Neoplasia in Inflammatory Bowel Disease
Al Sulais E, AlAmeel T, Alenzi M, Shehab M, AlMutairdi A, Al-Bawardy B. Colorectal Neoplasia in Inflammatory Bowel Disease. Cancers 2025, 17: 665. PMID: 40002259, PMCID: PMC11853504, DOI: 10.3390/cancers17040665.Peer-Reviewed Original ResearchRisk of colonic neoplasiaColonic neoplasiaInflammatory bowel diseaseConcomitant primary sclerosing cholangitisRisk factorsMultiple risk factorsColorectal neoplasiaBowel diseaseHigh-risk featuresIncreased riskPrimary sclerosing cholangitisColonic Crohn's diseaseColonic dysplasiaDisease extentSclerosing cholangitisRiskCrohn's diseaseNeoplasiaUlcerative colitisDiseaseSurveillancePatientsColorectalEpidemiology
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply